Oncostellae Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 12

Oncostellae General Information

Description

Developer of molecule drugs designed to focus on the treatment of autoimmune diseases. The company's drugs are created with innovative scaffolds that modulate clinically validated therapeutic targets in oncology, inflammatory, and autoimmune diseases, enabling hospitals to provide treatment for cancer and other serious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Edificio Feuga
  • D.5 Rua Lope Gomez De Marzoa, S/N
  • 15705 Santiago de Compostela
  • Spain
+34 637
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Edificio Feuga
  • D.5 Rua Lope Gomez De Marzoa, S/N
  • 15705 Santiago de Compostela
  • Spain
+34 637

Oncostellae Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncostellae Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 01-Feb-2024 Completed Generating Revenue
10. Later Stage VC 01-Jun-2023 Completed Generating Revenue
9. Equity Crowdfunding 23-Nov-2022 Completed Generating Revenue
8. Later Stage VC 23-Nov-2022 Completed Generating Revenue
7. Later Stage VC 23-Jun-2022 Completed Generating Revenue
6. Later Stage VC (Series 2) 22-Dec-2020 Completed Generating Revenue
5. Later Stage VC 17-May-2019 Completed Generating Revenue
4. Later Stage VC 17-Apr-2018 Completed Generating Revenue
3. Early Stage VC 26-Jul-2017 $2.12M $2.4M Completed Startup
2. Seed Round 12-Feb-2016 $274K $274K Completed Startup
To view Oncostellae’s complete valuation and funding history, request access »

Oncostellae Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares 8,140 $10.874565 $247.15 $247.15 1x $247.15 19.6%
Ordinary Shares 1,408 $10.874565 $193.09 $193.09 1x $193.09 3.39%
To view Oncostellae’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Oncostellae Patents

Oncostellae Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators Active 06-Nov-2017
CA-3079804-A1 Dihydropyridin derivatives as androgen receptor and glucocorticoid receptor modulators Pending 06-Nov-2017
AU-2018361566-A1 New analogs as androgen receptor and glucocorticoid receptor modulators Active 06-Nov-2017
AU-2018361566-B2 New analogs as androgen receptor and glucocorticoid receptor modulators Active 06-Nov-2017
EP-3480201-A1 New analogs as androgen receptor and glucocorticoid receptor modulators Inactive 06-Nov-2017 C07D495/04
To view Oncostellae’s complete patent history, request access »

Oncostellae Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncostellae Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Enisa National Innovation Company Lender/Debt Provider Minority
Inicio - Ministerio de Ciencia, Innovación y Universidades Government Minority
Innvierte Economia Sostenible Venture Capital Minority
Ministerio de Economía, Industria y Competitividad Government Minority
Noso Capital PE/Buyout Minority
You’re viewing 5 of 12 investors. Get the full list »

Oncostellae FAQs

  • When was Oncostellae founded?

    Oncostellae was founded in 2013.

  • Where is Oncostellae headquartered?

    Oncostellae is headquartered in Santiago de Compostela, Spain.

  • What is the size of Oncostellae?

    Oncostellae has 10 total employees.

  • What industry is Oncostellae in?

    Oncostellae’s primary industry is Drug Discovery.

  • Is Oncostellae a private or public company?

    Oncostellae is a Private company.

  • What is Oncostellae’s current revenue?

    The current revenue for Oncostellae is .

  • How much funding has Oncostellae raised over time?

    Oncostellae has raised $13.4M.

  • Who are Oncostellae’s investors?

    Enisa National Innovation Company, Inicio - Ministerio de Ciencia, Innovación y Universidades, Innvierte Economia Sostenible, Ministerio de Economía, Industria y Competitividad, and Noso Capital are 5 of 12 investors who have invested in Oncostellae.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process